January 07, 2021
A New York federal judge on Wednesday gave preliminary approval to a $2.4 million settlement to end claims from investors that Swedish biotechnology company Oasmia Pharmaceutical AB hid deals it had with two other companies owned by its founder and a former board member.
July 30, 2019
Investors for Swedish cancer biotechnology firm Oasmia launched a proposed class action lawsuit in New York federal court Monday, alleging the company actively concealed a number of deals involving entities owned by the biotech's founder and a former board member.